VANCOUVER, CANADA – August 3, 2017 – Evasc Neurovascular Enterprises ULC announced today the upcoming presentation of “A multi-center study evaluating the safety, technical feasibility, and efficacy of the eCLIPs for the treatment of bifurcation intracranial aneurysms,” the EESIS trial. The study overview will be presented by Dr. Joost de Vries, principal investigator, of Radboud University’s Department of Neurosurgery during the 9th ESMINT Congress, taking place September 7-9, 2017 in Nice, France. The presentation will take place at 5:00pm on Thursday, September 7 at theNice Acropolis Convention Centre.
In March 2016 Evasc commenced the EESIS study, which is designed to evaluate the safety, technical feasibility, and efficacy of the eCLIPs Bifurcation Remodeling System for the treatment of bifurcation intracranial aneurysms. The Presentation will show the very positive early data by outlining the EESIS trial and reviewing the outcomes of the pre-trial cases that met EESIS criteria.
In development since 2008, eCLIPs is a patented endovascular device designed to treat 95% of cerebral aneurysm cases, and is currently targeted for use in challenging wide-neck bifurcations. eCLIPs combines the best properties of stents and diverters, and can be used for coil retention and to enhance flow disruption. eCLIPs avoids dangerous entry into the dynamic, fragile environment of the aneurysm sac, while protecting and providing a platform for endothelial growth across the bifurcation neck. To date, eCLIPs has been used to treat cerebral aneurysms in over 40 patients in Canada and 8 European countries.
Evasc Neurovascular is a privately held medical device company focused on the development of disruptive endovascular treatments for cerebral aneurysms. Evasc received approval for the use of eCLIPs in Canada under the Special Access Program in 2013 and received CE mark approval in 2015. Evasc is headquartered in Vancouver, Canada.
Evasc Neurovascular is on the web at www.evasc.com.
For more information, contact Scott Wilson at +1 (604) 742-3811, email@example.com.